03.03.2017 • NewsDede Willamsk-resinSBC

Styrolution Completes K-Resin Buy

Kevin McQuade, CEO of Ineos Styrolution, said this acquisition – the first...
Kevin McQuade, CEO of Ineos Styrolution, said this acquisition – the first since BASF exited the company – underlines the company’s strategy of focusing on styrenic specialties, a balanced split across focus industries and a global presence.

Germany-based styrenics producer Ineos Styrolution has completed its acquisition of the global K-Resin styrene-butadiene copolymers (SBC) business of Chevron Phillips Chemical and Daelim after receiving all necessary regulatory and legal approvals.

Agreed in November last year, the acquisition includes the equity interests of the joint venture  K R Copolymer Company (KRCC), owned to 60% and 40% by the US and Korean companies respectively, as well as intellectual property for K-Resin and other assets related to the SBC business.

KRCC’s SBC plant is located in Yeosu, on the southern coast of South Korea, while Ineos Styrolution’s plant is at Ulsan.  The SBC portfolio to be added to the German company’s offering includes three brands targeting the packaging and healthcare markets:  K-Resin, Styrolux and Styroflex.

Kevin McQuade, CEO of Ineos Styrolution, said this acquisition – the first since BASF exited the company – underlines the company’s strategy of focusing on styrenic specialties, a balanced split across focus industries and a global presence.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.